Harvard Bioscience (HBIO) Stock Price, News & Analysis

Company Overview

Harvard Bioscience, Inc. is a developer and manufacturer of research tools and laboratory equipment that support the life sciences industry. The company’s offerings span two primary segments: Research & Discovery, which provides precision instrumentation and consumables for preclinical drug discovery and basic research; and Bioprocess, which delivers bioreactor systems and chromatography solutions for downstream processing in biopharmaceutical manufacturing. Its portfolio includes perfusion bioreactors, microfluidic platforms, medical research systems, and automated liquid handling instruments designed to accelerate scientific discovery and optimize laboratory workflows.

The company’s products serve a diverse customer base comprising academic institutions, government research agencies, biotechnology and pharmaceutical companies, and contract research organizations. Its consumable products—such as electrodes, pumps, and flow meters—are designed for compatibility with its core instrumentation, enabling integrated solutions across cell biology, electrophysiology, pharmacology and bioprocessing applications. Many instruments incorporate digital interfaces and software to facilitate data collection, process control and remote monitoring.

Founded to commercialize the century-old legacy of Harvard Apparatus, the business consolidated under the Harvard Bioscience name in the early 2000s and became publicly listed on the NASDAQ exchange. Headquartered in Holliston, Massachusetts, the company maintains research and manufacturing facilities in North America and Europe, with additional sales offices across Asia, reinforcing its global footprint. It works closely with customers to customize solutions for both routine laboratory needs and complex bioprocess challenges.

Under the leadership of President and Chief Executive Officer James P. Sharp, Harvard Bioscience continues to focus on innovation and strategic partnerships. The management team emphasizes operational efficiency, targeted R&D investments and acquisitions that expand the company’s technological capabilities. By aligning its product roadmap with emerging trends—including single-cell analysis, continuous bioprocessing and advanced automation—Harvard Bioscience aims to support the next generation of life sciences breakthroughs.

Key Stats

• Today's Range: $0.43 to $0.45
• 50-Day Range: $0.28 to $0.67
• 52-Week Range: $0.28 to $3.60
• Volume: 621,050 shs
• Average Volume: 3.16 million shs
• Market Capitalization: $19.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Moderate Buy

Harvard Bioscience Stock Analysis - MarketRank™

Harvard Bioscience scored higher than 85% of companies evaluated by MarketBeat, and ranked 135th out of 666 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Harvard Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Harvard Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Harvard Bioscience is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harvard Bioscience is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harvard Bioscience has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.36% of the float of Harvard Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Harvard Bioscience has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Harvard Bioscience has recently decreased by 42.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harvard Bioscience does not currently pay a dividend.

Dividend Growth

Harvard Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.14

Percentage of Shares Shorted

4.36% of the float of Harvard Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Harvard Bioscience has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Harvard Bioscience has recently decreased by 42.40%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: -0.21

News Sentiment

Harvard Bioscience has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Computer and Technology companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for Harvard Bioscience this week, compared to 8 articles on an average week.

Search Interest

Only 3 people have searched for HBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Harvard Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harvard Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.50% of the stock of Harvard Bioscience is held by insiders.

Percentage Held by Institutions

80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HBIO Stock Analysis - Frequently Asked Questions

How have HBIO shares performed this year?

Harvard Bioscience's stock was trading at $2.11 at the beginning of the year. Since then, HBIO shares have decreased by 78.9% and is now trading at $0.4447.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) released its earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. The medical instruments supplier earned $29.66 million during the quarter, compared to analyst estimates of $28.10 million. Harvard Bioscience had a negative trailing twelve-month return on equity of 4.96% and a negative net margin of 63.51%.

Does Harvard Bioscience have any subsidiaries?

The following companies are subsidiaries of Harvard Bioscience: Data Sciences International.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), Stag Industrial (STAG) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 7/11/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: INSTRU - SCIENTFC
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:HBIO
• CIK: 1123494
• Web: www.harvardbioscience.com
• Phone: (508) 893-8999
• Fax: 508-429-5732
• Employees: 490
• Year Founded: 1901

Price Target and Rating

• Average Price Target for Harvard Bioscience: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +574.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.40 million
• Net Margins: -63.51%
• Pretax Margin: -63.43%
• Return on Equity: -4.96%
• Return on Assets: -2.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.81
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: $91.40 million
• Price / Sales: 0.22
• Cash Flow: $0.10 per share
• Price / Cash Flow: 4.53
• Book Value: $1.45 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 44,214,000
• Free Float: 40,014,000
• Market Cap: $19.66 million
• Optionable: Optionable
• Beta: 1.52